We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Mucosave® on Gastrointestinal Discomfort

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04119817
Recruitment Status : Completed
First Posted : October 8, 2019
Last Update Posted : February 5, 2020
Sponsor:
Information provided by (Responsible Party):
Azienda Ospedaliera Universitaria Policlinico "G. Martino"

Tracking Information
First Submitted Date  ICMJE September 19, 2019
First Posted Date  ICMJE October 8, 2019
Last Update Posted Date February 5, 2020
Actual Study Start Date  ICMJE February 9, 2019
Actual Primary Completion Date May 22, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 4, 2020)
  • Evaluation of relief of gastrointestinal disorders with the Gastrointestinal Quality of Life Index (GIQLI) questionnaire. [ Time Frame: 8 weeks ]
    The Gastrointestinal Quality of Life Index (GIQLI) questionnaire contains questions on gastrointestinal symptoms, each with 5 answers in the "Likert scale" style (technique for measuring the attitude), according to the meaning "higher score, better quality of life". The GIQLI is an appropriate, validated and potentially useful tool to assess health-related quality of life in clinical studies of patients with gastrointestinal disease. Each of the 36 items is scored on a five-point scale (0 to 4) denoting the burden of the particular symptom or dysfunction. The total score ranged from 0 (worst) to 144 (best quality of life) with higher scores representing better quality of life. Subscales can be summarized or averaged.
  • Evaluation of relief of gastrointestinal symptoms with the Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS): an evaluation scale of gastrointestinal symptoms. [ Time Frame: 8 weeks ]
    GSAS is a 15-item tool designed to evaluate various aspects including stress about gastrointestinal symptoms before and after treatments. GSAS is a self-administered questionnaire that asks patients to report about the previous week for 15 specific symptoms: heartburn, a feeling of pressure inside chest, food coming back into mouth, an acid in mouth, frequent gurgling, feeling of lump in throat, nausea, burning pain in throat, bloating, belching, flatulence, feeling full after eating, bad breath, coughing, and hoarseness. Scoring of the GSAS distress subscale is based on the presence of the symptoms and their bother ratings. Specifically, patients first indicate whether they had the symptom in the past week. If they did not have the symptom, their score for the symptom is 0. If they did have the symptom, they then report how bothered they were by it on a 4-point scale (0 ? not at all, 1 ? somewhat, 2 ? quite a bit, 3 ? very much). Subscales can be summarized or averaged.
Original Primary Outcome Measures  ICMJE
 (submitted: October 7, 2019)
  • Evaluation of relief of gastrointestinal disorders with the Gastrointestinal Quality of Life Index (GIQLI) questionnaire. [ Time Frame: 8 weeks ]
    The Gastrointestinal Quality of Life Index (GIQLI) questionnaire contains questions on gastrointestinal symptoms, each with 5 answers in the "Likert scale" style (technique for measuring the attitude), according to the meaning "higher score, better quality of life".
  • GSAS: an evaluation scale of gastrointestinal symptoms. [ Time Frame: 8 weeks ]
    The GSAS is a 15-item tool designed to evaluate various aspects including stress about gastrointestinal symptoms before and after treatments. It is a simple and easy to understand tool that can be administered in a relatively short time. GSAS is valid, stable and sensitive to changes in symptom over time.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: October 7, 2019)
  • Satisfaction of supplementation. [ Time Frame: 15 days ]
    Each participant received a daily diary in which they found a few simple multiple choice questions, which helped the investigators to establish the individual degree of satisfaction of treatment. Each participant was asked to answer for the first 15 days of treatment with Mucosave® or placebo to the following questions: How are you today?, How are you compared to yesterday?, Have you had heartburn today?, have you had abdominal swelling today?, Have you had belching today?, Which symptoms were improved today?.
  • Intestinal microbiota investigation on stool samples [ Time Frame: 8 weeks ]
    Each participant will collect a stool sample before and another at the end of period of supplementation for intestinal microbiota investigation .
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Effects of Mucosave® on Gastrointestinal Discomfort
Official Title  ICMJE Clinical Study on the Effects of the Product Mucosave® on Gastrointestinal Discomfort and the Quality of Life in Healthy Volunteers
Brief Summary Gastrointestinal (GI) discomfort, which often includes gastroesophageal reflux disease (GERD) is a common disorder in healthy adults affecting 20% of people particularly women. The disorders related to GI discomfort usually have a huge impact on the quality of life. Current treatment for GERD are associated with side effects. In this study, researchers designed a randomized double-blind placebo-controlled trial to assess the effect of Mucosave® on the symptoms and quality of life of healthy adults with gastrointestinal discomfort. One hundred healthy subjects with GI discomfort were enrolled in the study and divided in two groups: 60 and 40 taking for 8 weeks Mucosave® (400 mg/day) or placebo (400 mg/day). To evaluate the effects of treatment, the questionnaires Gastrointestinal Quality of Life index (GIQLI) and GERD Symptom Assessment Scale (GSAS) were self-administered by participants before the beginning of period of supplementation (T0), after four weeks (T4) during the period of supplementation and after 8 weeks (T8) at the end of supplementation.
Detailed Description

Gastrointestinal (GI) discomfort is a common disorder in healthy adults with a prevalence of 20%, particularly affecting women. Gut health is gaining more interest nowadays for a variety of reasons including the well-established link between the body and mind via the brain-gut axis. As a result of this connection, GI discomfort is usually accompanied by psychosocial factors such as stress and mood disorders. The quality of life can therefore be reduced as there is also the occurrence of wide range of disorders, including abdominal pain, sense of fullness, nausea, sense of swelling, flatulence, bowel movements, constipation, eructation, heartburn and reflux. Gastroesophageal reflux disease (GERD), which is one of the most frequent causes of GI discomfort, is a chronic and relapsing disorder that occurs when the stomach content reflux into the esophagus. The condition is common in Western countries with a prevalence estimated to be about 10-20% while in Asia the occurrence is lower (5%) but is expected to increase in a near future. In the United State, 44% of the population report having GERD symptoms at least once a month and 20% at least once a week. Due to the accelerated pace of life in recent years with an important change in lifestyle, there is an increase in GERD incidence. Although GERD is not life threatening, it is characterized by important impairment in health related quality of life (HRQL) including a decrease in productivity comparable to that of other chronic diseases. In fact, HRQL has been demonstrated to be poorer in subjects with frequent upper gastrointestinal tract symptoms compared to those with no symptoms as measured by the Psychological General Well-Being Index . Beside the typical GERD symptoms like regurgitation and heartburn, impairment of quality of life include disturbed sleep, body pain, anxiety and unsatisfactory sex life. The reflux episodes can occur on daytime but nocturnal symptoms have an important influence on life quality and are associated to the complications of GERD. In addition, GERD symptoms impose a substantial cost on healthcare systems. Non pharmacological treatment of GERD include avoiding alcohol, coffee, smoking and reducing body weight. On the other hand, current pharmacological treatment primarily focuses on the use of proton pump inhibitors (PPIs) for the inhibition of gastric secretion. However, there is a persistence of troublesome GERD symptoms in 20-30% of patients after a daily treatment with a standard PPI dose. According to World Health Organization, about 80% of people in developing countries rely on herbal medicine as the first line of treatment. Natural plants present an interesting option for the management of gastrointestinal disorders. Opuntia ficus-indica (L.) also known as prickle pear is a tropical and subtropical plant usually growing in arid climates especially in the Mediterranean and Central America regions thanks to it special adaptative mechanism. In Sicily traditional medicine the plant's cladodes are used in the treatment of gastric ulcer. This traditional use has been confirmed by scientific studies, suggesting the mucoadhesion effect due to the polysaccharides content of cladodes. Wound healing properties are also attributed to Opuntia ficus-indica when topically applied on rats. On the other hand, Olea europea (Olive) is a mediterranean plant which leaves extract has been shown to prevent experimental formation of gastric lesions induced by stress. Other biological activities of olive leaves include anti-inflammatory and antioxidant thanks to its abundance in polyphenols. Furthermore, a significant correlation has recently been demonstrated between gastrointestinal discomfort and microbial dysbiosis. On this basis, the role of intestinal microbiota is emerging along with its importance as a new target for treatment.

A previous clinical study reported the efficacy and the safety for GERD treatment as a medical device based on sodium alginate/bicarbonate in combination with Mucosave®, a blend of extracts from Opuntia ficus-indica cladodes and Olea europea leaves . In this study, researchers performed a double-blinded randomized-controlled trial to assess the efficacy of Mucosave® as a sole primary therapy in healthy adults with gastrointestinal discomfort. The questionnaires used were the Gastrointestinal Quality of life Index (GIQLI) to evaluate the impact of the disorders on the quality of life and the GERD Symptom Assessment Scale (GSAS) designed to assess various aspects of GERD. Efficacy in reducing gastrointestinal disorders was also measured by the completion of a subjective daily diary.

Potential participants were subjected to a short medical visit and the inclusion and exclusion criteria were assessed and the possibility of inclusion in the study established. The study was performed in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained before subjects enrollment.

Calculation of the sample size The sample size was estimated considering as primary endpoint, the increase of the GIQLI score in the study period. Data in the literature show that healthy subjects have a GIQLI score variability value of 13.00 and in the present study included subjects with a GIQLI score not lower than 90.00. Therefore, considering a value (δ) of clinically relevant increase of the score equal to 10, an α value equal to 0.05 and a study power of 80%, 55 patients were required to carry out the experimentation. In order to guarantee the power, a possible abandonment rate of 8% was also considered, consequently a total number of 60 subjects supplied with Mucosave® is necessary to be guaranteed the endpoint of the study.

Screening and Randomisation Before enrollment subjects were asked to respond to the GIQLI and GSAS questionnaires with the aim to establish basal level score of participants.

Intervention Allocation of participants into the group supplied with Mucosave® or placebo was performed through computerized randomization. A total of 100 participants were enrolled. They were divided in two groups: 60 healthy volunteers taking 400 mg/day of Mucosave® capsules and 40 healthy volunteers taking capsules of placebo for a period of 8 weeks, once a day after dinner before going to bed. Mucosave® (Bionap srl, Italy) is a blend of two enriched extracts from Opuntia ficus-indica cladodes (32-35% w/w) and Olea europea (olive) leaves (23-25% w/w) with a total polyphenol amount of 3.7-4.3% as luteolin 7-O-glucoside with maltodextrin as support.

Assessment Compliance with test beverage consumption was self- recorded daily by participants in a diary. Subjects were reminded of the behavioural modalities related to the study: dosage of treatment and abstinence from taking anti-reflux drugs such as PPIs, histamine-2 blockers, agents facilitating motility or other antacids.

The primary endpoint of the study was defined as relief of gastrointestinal disorders evaluated by GIQLI and GSAS at the beginning (T0), after four weeks (T4) and eight weeks (T8) of supplementation period between the group of subjects supplied with Mucosave® and group supplied with placebo.

The Gastrointestinal Quality of Life Index (GIQLI) questionnaire contains 36 questions, each with 5 answers in the "Likert scale" style (technique for measuring the attitude): the range goes from 0 (always answer with letter "a") to 144 (always answer with letter "e"), according to the meaning "higher score, better quality of life". Patients with more severe gastro-intestinal disorders generally reach an average score corresponding to 45 points, compared to the median score 126 of healthy controls. Investigators analyzed answers and evaluated the scores only for the following disorders: abdominal pain, sense of fullness, sense of swelling, flatulence, eructation, bowel sounds, bowel movements, reflux, constipation, nausea and heartburn. Increase in scores corresponds to reduction of disorders.

GSAS is the most complete evaluation scale of gastrointestinal symptoms. The GSAS is a 15-item tool designed to evaluate various aspects including stress about gastrointestinal symptoms before and after treatments. It is a simple and easy to understand tool that can be administered in a relatively short time. GSAS is valid, stable and sensitive to changes in symptom over time.

At the same time each participant received a daily diary in which they found a few simple multiple choice questions, which helped the investigators to establish the individual degree of satisfaction of treatment. Each participant was asked to answer for the first 15 days of treatment with Mucosave® or placebo to the following questions: How are you today?, How are you compared to yesterday?, Have you had heartburn today?, have you had abdominal swelling today?, Have you had belching today?, Which symptoms were improved today?.

The symptom diaries and questionnaires were coded and anonymized. Codes were broken only after the raw data had been entered into the database.

Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Randomized, controlled, double blind study
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Condition  ICMJE Gastrointestinal Discomfort
Intervention  ICMJE
  • Dietary Supplement: Mucosave® capsules
    400 mg/day of Mucosave® capsules for a period of 8 weeks, once a day.
  • Dietary Supplement: Placebo
    400 mg/day of placebo capsules for a period of 8 weeks, once a day.
Study Arms  ICMJE
  • Experimental: Mucosave® capsules
    60 healthy volunteers taking 400 mg/day of Mucosave® capsules for a period of 8 weeks, once a day after dinner before going to bed.
    Intervention: Dietary Supplement: Mucosave® capsules
  • Placebo Comparator: Placebo
    40 healthy volunteers taking capsules of placebo for a period of 8 weeks, once a day after dinner before going to bed.
    Intervention: Dietary Supplement: Placebo
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: October 7, 2019)
100
Original Actual Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE July 22, 2019
Actual Primary Completion Date May 22, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • healthy men and women aged between 30 and 50 years;
  • subjects able to read, to understand and to sign approval of informed consent;
  • subjects not using food supplements for gastro-intestinal well-being;
  • subjects available to continue own habitual diet;
  • subjects without diagnosis of clinical diseases with relevant effects on the gastrointestinal system or visceral motility;
  • subjects with reduced bowel movements defined as an average of > 1 and ≤ 3.5 stools per week in the last 6 months;
  • subjects with BMI = 18-30 kg/m2;
  • non-smoker subjects.

Exclusion Criteria:

  • history of gastroesophageal surgery or endoscopic therapy due to severe erosive esophagitis;
  • presence of Barrett's esophagus;
  • subjects with uncontrolled or severe medical problems such as asthma, angina, hepatic or kidney diseases;
  • subjects aged < 30 or > 50 years;
  • presence of acute or chronic inflammatory processes requiring therapy;
  • presence of acute or chronic coexisting diseases (cardiovascular, gastrointestinal, endocrinological, immunological, metabolic or any other condition that contraindicates, in the opinion of the investigators, the participation to the study);
  • subjects taking drugs that, in the opinion of the investigator, may interfere with the objectives of the study or represent a safety risk or can confuse the interpretation of the study results including heartburn medication, probiotics and prebiotics;
  • subjects that, in the opinion of the investigator, can be considered as potential participants, but for whatever reason are not able to respect the protocol of the study;
  • pregnant or nursing women;
  • subjects who cannot receive treatment with experimental drugs; subject participating in a recent experimental study (this must have been performed no less than 30 days prior to this study);
  • subjects affected by neoplasms.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 30 Years to 50 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Italy
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04119817
Other Study ID Numbers  ICMJE MUCOGASDISCOMFORT
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Current Responsible Party Azienda Ospedaliera Universitaria Policlinico "G. Martino"
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Azienda Ospedaliera Universitaria Policlinico "G. Martino"
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Gioacchino Calapai, MD Azienda Ospedaliera Universitaria "G Martino", Messina, Italy.
PRS Account Azienda Ospedaliera Universitaria Policlinico "G. Martino"
Verification Date January 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP